Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocin IV PK in Healthy Volunteers
NCT03291158Phase 1Withdrawn
- Sponsor
- Rempex Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of minocycline in bacterial infection and pneumonia, sponsored by Rempex Pharmaceuticals. Primary endpoint: Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Minocycline at 16 weeks. Planned start Apr 2018; status: withdrawn.
02
Drugs
minocycline
03
Conditions
bacterial infectionpneumonia
Beyond the preview
Go deeper on NCT03291158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03291158.